Bioactive agent for bone tissue engineering
AssigneeUniversity of Connecticut
InventorsCato T. Laurencin, Wai Hong Lo
Life of this patent
Estimating the term…
Abstract
Inventors have discovered a method for inducing bone formation in a patient in need thereof comprising administering an effective amount of benzoyladenosine-3′,5′-cyclic monophosphate (6-Bnz-cAMP) to the patient. Systems for bone tissue engineering, comprising a polymer-based scaffold, such as a PLAGA scaffold and an effective amount of 6-Bnz-cAMP are also disclosed herein.
Claims18
A method for inducing bone formation in a patient in need thereof comprising administering an effective amount of benzoyladenosine-3′,5′-cyclic monophosphate (6-Bnz-cAMP) or a pharmaceutically acceptable salt thereof to the patient.
A system for bone tissue engineering comprising:
- a polymer-based scaffold and 6-Bnz-cAMP or a pharmaceutically acceptable salt thereof.
The system of claim 2, wherein the polymer-based scaffold comprises 14. The system of claim 12, wherein the polymer having documented degradability and bio compatibility comprises poly(lactic-co-glycolide) (PLAGA).
A method of tissue engineering comprising:
- contacting pre-osteoblast cells on PLAGA scaffolds with an effective concentration of N6-Benzoyladenosine-3′,5′-cyclic monophosphate (6-Bnz-cAMP).
A method of preparing osteoblasts or osteoblast-like cells for use in bone tissue engineering comprising:
- contacting pre-osteoblast cells on PLAGA scaffolds with an effective concentration of N6-Benzoyladenosine-3′,5′-cyclic monophosphate (6-Bnz-cAMP);
- promoting initial cell adhesion and cell proliferation of such cells, and
- thereby inducing differentiation of cells to osteoblasts or osteoblast-like cells on PLAGA scaffolds.
Dependencies are inferred from the claim text.